NeurologyLive® Mind Moments® cover art

NeurologyLive® Mind Moments®

By: NeurologyLive
Listen for free

  • Summary

  • Mind Moments®, a podcast from NeurologyLive® (https://www.neurologylive.com/) , brings you exclusive interviews with experts in neurologic disorders. Listen in to hear the latest clinical and research updates from major medical conferences, as well as insights on the management of complex disorders, including epilepsy, migraine, Alzheimer disease, stroke, multiple sclerosis, Parkinson disease, and more. For more expert insight into neurology, visit NeurologyLive.com (https://www.neurologylive.com/) .
    Show More Show Less
Episodes
  • 118: Gaining Patient Perspectives on Impact of Narcolepsy

    118: Gaining Patient Perspectives on Impact of Narcolepsy
    Jun 28 2024
    Welcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.


    In this episode, Anne Marie Morse, DO, FAAN, a pediatric neurologist and sleep medicine specialist at Geisinger Medical Center, sat down at the 2024 SLEEP Annual Meeting to discuss a poster presentation highlighting a listening analysis that characterized the struggles and unmet needs of people with narcolepsy. in the discussion, Morse outlined some of the major findings, including the rates of missed and misdiagnosis, how cataplexy impacts daily life, and some of the other comorbidities associated with the condition. She spoke on the value of gaining patient perspectives and using their descriptions for their disorders helps in understanding true unmet needs. Furthermore, she spoke on the importance of a strong patient-clinician relationship, the ability to communicate openly, and the steps following diagnosis to ensure effective long-term treatment outcomes.


    Looking for more sleep disorders discussion? Check out the NeurologyLive® sleep disorders clinical focus page.

    Episode Breakdown:
    • 1:10 – Motivations behind conducting listening analysis
    • 3:15 – Major clinical takeaways from study; notable quality of life impairments in narcolepsy
    • 7:00 – Impact of cataplexy and patients' overreaction
    • 9:50 – Neurology News Minute
    • 12:20 – Reasons for missed and misdiagnosis
    • 14:50 – Early tips to pathing patients towards treatment success

    The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here:

    • FDA Grants Traditional Approval to Elevidys Gene Therapy for Ambulatory DMD, Accelerated Approval for Nonambulatory Patients
    • FDA Approves Efgartigimod as New Treatment for Chronic Inflammatory Demyelinating Polyneuropathy
    • FDA Approves Pitolisant for Excessive Daytime Sleepiness in Pediatric Narcolepsy

    Thanks for listening to the NeurologyLive® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.
    Show More Show Less
    19 mins
  • 117: 2024 Consortium of Multiple Sclerosis Centers Annual Meeting Highlights

    117: 2024 Consortium of Multiple Sclerosis Centers Annual Meeting Highlights
    Jun 14 2024
    Welcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.

    In this episode, we spoke with a variety of specialists in neurology who presented research and gave talks at the 2024 Consortium of Multiple Sclerosis Centers (CMSC) Annual Meeting, held May 29-June 2, in Nashville, Tennessee. Those included in this week's episode, in order of appearance, are:

    • Anthony Feinstein, PhD, FRCPC, MBBCh, a professor of psychiatry at the University of Toronto.
    • Brian G. Weinshenker, MD, a professor of neurology at the University of Virginia.
    • Douglas A. Wajda, PhD, an assistant professor of neurology and member of the Health and Human Performance Department in the College of Education at Cleveland State University.
    • Le Hua, MD, director of Clinical Operations and director of the Multiple Sclerosis Program at Cleveland Clinic's Lou Ruvo Center for Brain Health in Las Vegas, Nevada.
    • Eion P. Flanagan, MB, BCh, a professor of neurology and chief of the Division of Multiple Sclerosis and Autoimmune Neurology at Mayo Clinic; and director of the Autoimmune Neurology Fellowship.

    Want more from the 2024 CMSC Annual Meeting? Click here for all of NeurologyLive®'s coverage of CMSC 2024.

    Episode Breakdown:
    • 1:40 – Feinstein on the difficulties with improving fatigue in multiple sclerosis and the lack of improvement seen from approved disease-modifying therapies.
    • 5:20 – Weinshenker on the key diagnostic aspects of neuromyelitis optica spectrum disorder and how it differs from other similarly presenting autoimmune disorders.
    • 9:40 – Wajda on the use of the Cionic Neural Sleeve, the advantages it holds, and how it may be used to treat gait dysfunction in multiple sclerosis.
    • 12:00 – Hua on the differential diagnosis of pediatric-onset MS vs late-onset MS, and the notable biologic changes observed.
    • 19:30 – Flanagan on the diagnostic pearls for MOG-antibody associated disease and the importance of early recognition of this group.

    Thanks for listening to the NeurologyLive® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.
    Show More Show Less
    23 mins
  • 116: Understanding Vorasidenib's Therapeutic Benefit on Neurocognition, Seizure Control in Diffuse Gliomas

    116: Understanding Vorasidenib's Therapeutic Benefit on Neurocognition, Seizure Control in Diffuse Gliomas
    May 31 2024
    Welcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.


    In this episode, Katherine Peters, PhD, a neurologist and neurooncologist at the Preston Robert Tisch Brain Tumor Center at Duke University provided context on a new analysis from the phase 3 INDIGO trial, a study assessing vorasidenib in patients with mutant isocitrate dehydrogenase (mIDH) 1/2 diffuse gliomas. The conversation, which occurred at the 2024 AAN Annual Meeting, covered the covered the therapeutic potential of this agent and its impacts on quality of life, neurocognition, and seizure control. Peters, an expert in the field, provided insight on the mechanism of action of vorasidenib, the added value behind the exploratory analysis, and the next steps in research. Furthermore, she provided context on the patient sample observed and why these data may hold significant weight going forward.

    Looking for more neuromuscular discussion? Check out the NeurologyLive® epilepsy clinical focus page.

    Episode Breakdown:
    • 1:05 – Mechanism of action of vorasidenib, a mIDH 1/2 inhibitor
    • 2:00 – Overview of exploratory analysis results
    • 4:20 – Significance of new data, how it adds to previous primary and secondary outcomes
    • 5:50 – Neurology News Minute
    • 8:25 – Next steps for the study and use of vorasidenib
    • 10:35 – Remaining unmet needs for patients with diffuse gliomas

    The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here:

    • Diazepam Buccal Film’s Role in Treating Intermittent Pediatric Seizures, with Michael Rogawski, MD, PhD
    • Ocrelizumab Gains EU CHMP Positive Opinion for Subcutaneous Formulation to Treat MS
    • FDA Approves Sprinkle Formulation of Neurocrine Biosciences’ Valbenazine for Tardive Dyskinesia or Huntington disease Chorea

    Thanks for listening to the NeurologyLive® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.
    Show More Show Less
    14 mins
Physical Illness & Disease Hygiene & Healthy Living Science
Show More Show Less

What listeners say about NeurologyLive® Mind Moments®

Average Customer Ratings

Reviews - Please select the tabs below to change the source of reviews.

Audible.com.au reviews

Amazon Reviews
No Reviews are Available
In the spirit of reconciliation, Audible acknowledges the Traditional Custodians of country throughout Australia and their connections to land, sea and community. We pay our respect to their elders past and present and extend that respect to all Aboriginal and Torres Strait Islander peoples today.